Diethylamine

Diethylamine

SCHEMBL2361776

CCNCC.CCn1c2ccccc2c2cc(C(C)=O)c(O)cc21

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CCKAR

The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.53
MAPT P10636 10/20 0.50
KDM4E B2RXH2 9/20 0.50
LMNA P02545 7/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 4/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
BLM P54132 1/20 0.47
PTGES O14684 1/20 0.47
NPY5R Q15761 3/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
HCRTR1 O43613 1/20 0.45
RAB9A P51151 1/20 0.45
PAX8 Q06710 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14549005 0.84 SRC (0.53) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL28922531 0.80 NPSR1 (0.56) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL2361775 0.78 HIF1A (0.52) MAPTKDM4EMEN1KMT2ASMN1; SMN2
Diethylamine SCHEMBL14472230 0.77 KDM1A (0.51) NPSR1MAPTKDM4ELMNAMEN1
Diethylamine SCHEMBL14472125 0.75 NPSR1 (0.50) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL29808829 0.73 ALDH1A1 (0.59) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL21135536 0.73 ALDH1A1 (0.59) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL5662028 0.73 HPGD (0.72) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL13979310 0.72 KDM4E (0.70) NPSR1MAPTKDM4ELMNAMEN1
SCHEMBL1149228 0.72 MAPT (0.73) NPSR1MAPTKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, INC. (US) 2018-11-27 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, LLC (US) 2014-10-09 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
EP-2356093-A1 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (RU) 2011-08-17 EP disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 NPSR1 4038/4885MAPT 1792/4885KDM4E 4662/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 NPSR1 4038/4885MAPT 1792/4885KDM4E 4662/4885
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds MALT1, PAICS, BCL9 NPSR1 4038/4885MAPT 1792/4885KDM4E 4662/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT NPSR1 4030/4885MAPT 1806/4885KDM4E 4644/4885
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 NPSR1 4038/4885MAPT 1792/4885KDM4E 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.